Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028
A study by Triton Market Research on the European immunoglobulin market shows that it will progress with a CAGR of 6.81% during the forecasted period of 2022-2028.
The
countries studied in this market include:
• The United Kingdom
• Italy
• Spain
• France
• Germany
• Rest of Europe
The immunoglobulin market in
the region is primarily driven by the prevalence of various immunodeficiency
diseases found in the population. Alongside the government initiatives
regarding immunoglobulin and plasma donation and the biotechnology sector’s development,
the research and development of various vaccines are also expected to drive
market growth. Furthermore, this is expected to increase the demand for
technological advancement and innovative immunoglobulin systems.
In Germany, the research and
development activities relating to antibody development alongside the policies
and programs supported by the government are the growth promoters of the
market. For example, in 2020, to understand the prevalence of the coronavirus,
German scientists started a nationwide study for testing the measures to
prevent the spread of the virus. Furthermore, in the same year, the country
planned on launching its first antibody testing program, conducting a series of
blood tests to determine the number of people immune to infections and the ones
who were infected without knowledge. Thus, such factors are expected to
increase the market growth in Germany during the forecasted period.
Italy has also seen a rise in
the demand for immunoglobulin in recent years. The increase in the prevalence
of neurological diseases such as dementia, Alzheimer’s, and others drives the
demand for immunoglobulin. These diseases have been marked as the latest
postulated indications for the clinical use of immunoglobulin. Hence, the
increase in the prevalence of such a disease is expected to foster the immunoglobulin
market’s growth across the country in the forecast period.
Primary immunodeficiency
diseases are rare genetic disorders that weaken the immune system. Some of
these primary immunological deficiencies can lead to death. Depending on the
disease’s severity, primary immunodeficiency illnesses may be detected during
childhood, adolescence, or adulthood. The increasing prevalence and incidence
rates of autoimmune illnesses and immunodeficiency diseases are anticipated to
boost the demand for and acceptance of immunoglobulin products, which is
predicted to support market expansion throughout the forecast period.
The
studied report assesses the market’s growth based on type, delivery mode,
application, end-user and sales channel. Here, the application segment
comprises hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP),
myasthenia gravis, primary immunodeficiency diseases, chronic inflammatory
demyelinating polyneuropathy, multifocal motor neuropathy, Guillain-Barre
syndrome, inflammatory myopathies, specific antibody deficiency, and other
applications.
The
dominant players in the immunoglobulin market include Sichuan Yuanda Shuyang
Pharmaceutical Co Ltd, Biotest AG, ADMA Biologics, Shanghai RAAS Blood Products
Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, Takeda Pharmaceutical Company
Limited, and CSL Behring.
Founded in 1983, Octapharma AG
is the largest independent, privately-held plasma fractionator in the world. Headquartered
in Switzerland, Octapharma AG is one of the leading human protein product
manufacturers. High-quality human proteins used in the company’s medications
are derived from human plasma and human cell lines. The business focuses on
immunotherapy, hematology, and critical care as its three therapeutic areas.
Key
deliverables of the report:
· Market CAGR during the forecasting years 2022-2028
· Detailed data highlighting key insights, industry components, and market strategies
· Comprehensive information and estimation of the immunoglobulin market revenue growth in Europe and its influence on the parent market
· In-depth study of forthcoming trends in consumer behavioral patterns
· A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces Model
· A wide-ranging study of factors that will challenge the Europe immunoglobulin
market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. EUROPE
IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. EUROPE
IMMUNOGLOBULIN MARKET OUTLOOK - BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. EUROPE
IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. EUROPE
IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER APPLICATIONS
6. EUROPE
IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. EUROPE
IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. EUROPE
IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. UNITED
KINGDOM
8.2. GERMANY
8.3. FRANCE
8.4. SPAIN
8.5. ITALY
8.6. REST
OF EUROPE
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA
LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: EUROPE IMMUNOGLOBULIN
MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: EUROPE IMMUNOGLOBULIN
MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: EUROPE IMMUNOGLOBULIN
MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: EUROPE IMMUNOGLOBULIN
MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: EUROPE IMMUNOGLOBULIN
MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: EUROPE IMMUNOGLOBULIN
MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: EUROPE IMMUNOGLOBULIN
MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: EUROPE
IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: EUROPE
IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: EUROPE
IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: EUROPE
IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: EUROPE
IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: EUROPE
IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: EUROPE
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: EUROPE
IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: EUROPE
IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: EUROPE
IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: EUROPE
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: EUROPE
IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: EUROPE
IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY,
2022-2028 (IN $ MILLION)
FIGURE 15: EUROPE
IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $
MILLION)
FIGURE 16: EUROPE
IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: EUROPE
IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: EUROPE
IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028
(IN $ MILLION)
FIGURE 19: EUROPE
IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: EUROPE
IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: EUROPE
IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: EUROPE
IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: EUROPE
IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: EUROPE
IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: EUROPE
IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: EUROPE
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: EUROPE
IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: EUROPE
IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: EUROPE
IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: EUROPE IMMUNOGLOBULIN
MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: UNITED KINGDOM
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: GERMANY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: FRANCE
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: SPAIN
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: ITALY
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: REST OF EUROPE
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)